{"nct_id":"NCT05870748","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","status_verified_date":"2025-04","start_date":"2023-07-12","start_date_type":"ACTUAL","primary_completion_date":"2025-08-26","primary_completion_date_type":"ACTUAL","completion_date":"2025-08-26","completion_date_type":"ACTUAL","phases":["PHASE2","PHASE3"],"tickers":["STRO"]}